subject: New anti-platelet drug clopidogrel was better than for Kage Lei [print this page] New anti-platelet drug clopidogrel was better than for Kage Lei
The PLATO trial involving a total of 18,624 cases for ACS (with or without ST segment elevation) hospitalized patients. Patients were randomized to receive for the Kage Lei (180 mg first dose, then 90 mg twice daily) or standard dose of clopidogrel (300 to 600 mg first dose, followed by 75 mg / day); all patients received aspirin at the same time . The results showed that 12 months of treatment, for patients treated with a combination of Kage Lei end of the event (due to vascular causes, myocardial infarction, or stroke death) rate was 9.8%, 11.7% of clopidogrel group. Kage Lei on cardiovascular events for the death and the role of myocardial infarction was significantly lower than clopidogrel, but the incidence of stroke in two groups of non-discrimination. The former full-cause mortality was also lower than the latter (4.5% vs 5.9%). The incidence of bleeding, two groups (11.6% on 11.2%), but coronary artery bypass graft (CABG) bleeding not related to the incidence of treatment group for the Kage Lei is higher (4.5% vs 3.8%). Other side effects seen more often with breathing difficulties and heart rate slow, but most of the attacks lasted less than one week and only a small number of patients stopped treatment because of side effects. Researchers also noted that patients with different results in different regions. North America and Asia on the 1,814 cases of patients shows that clopidogrel is more effective than for the Kage Lei, 12 months in the treatment of primary efficacy event rates were 9.6% and 11.9%. But the researchers think this may be by chance, in North America and in other parts of the result of recruitment of differences between patients may be geographical differences between patient groups, or influence the results of randomized treatment of different modes of operation.
